Lantern Pharma (LTRN) to Release Quarterly Earnings on Tuesday

Lantern Pharma (NASDAQ:LTRNGet Rating) is scheduled to issue its quarterly earnings data after the market closes on Tuesday, May 3rd. Parties interested in registering for the company’s conference call can do so using this link.

Lantern Pharma (NASDAQ:LTRNGet Rating) last released its quarterly earnings data on Thursday, March 10th. The company reported ($0.31) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.40) by $0.09. On average, analysts expect Lantern Pharma to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

NASDAQ:LTRN opened at $6.51 on Tuesday. Lantern Pharma has a 1-year low of $5.45 and a 1-year high of $16.94. The company has a 50-day moving average of $6.68 and a 200 day moving average of $7.69. The firm has a market cap of $70.18 million, a PE ratio of -5.81 and a beta of 1.64.

Institutional investors have recently made changes to their positions in the business. Bank of America Corp DE increased its holdings in shares of Lantern Pharma by 5,377.5% during the second quarter. Bank of America Corp DE now owns 2,191 shares of the company’s stock valued at $32,000 after acquiring an additional 2,151 shares in the last quarter. JPMorgan Chase & Co. acquired a new position in shares of Lantern Pharma during the fourth quarter valued at about $42,000. Citadel Advisors LLC acquired a new position in shares of Lantern Pharma during the fourth quarter valued at about $89,000. Wells Fargo & Company MN increased its holdings in shares of Lantern Pharma by 103.8% during the second quarter. Wells Fargo & Company MN now owns 7,423 shares of the company’s stock valued at $109,000 after acquiring an additional 3,780 shares in the last quarter. Finally, Millennium Management LLC acquired a new position in shares of Lantern Pharma during the third quarter valued at about $142,000. Institutional investors and hedge funds own 15.56% of the company’s stock.

LTRN has been the subject of a number of recent research reports. HC Wainwright boosted their target price on shares of Lantern Pharma from $34.00 to $36.00 and gave the stock a “buy” rating in a report on Friday, March 11th. Colliers Securities reiterated a “buy” rating on shares of Lantern Pharma in a report on Tuesday, March 22nd.

Lantern Pharma Company Profile (Get Rating)

Lantern Pharma Inc, a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer.

Recommended Stories

Earnings History for Lantern Pharma (NASDAQ:LTRN)

Receive News & Ratings for Lantern Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lantern Pharma and related companies with MarketBeat.com's FREE daily email newsletter.